

Contents

Clinical Studies

- 537 Efficacy of Lipophilic Statins on Outcomes of Patients Treated with Immune Checkpoint Inhibitors**
Chiang, C.-H. (Boston, MA/Taipei); Chen, Y.-J. (Taipei); See, X.Y. (Rochester, NY); Chang, Y.-C.; Wang, S.-S. (Taichung); Peng, C.-Y. (Danbury, CT); Horng, C.-S. (Taichung); Hsia, Y.P. (New Taipei City); Chiang, C.-H. (Taipei/New Taipei City); Peng, C.-M.; Chiang, C.-H. (Taichung)
- 542 Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings**
Ohama, H.; Hiraoka, A. (Matsuyama); Tada, T. (Himeji); Hirooka, M. (Toon); Kariyama, K. (Okayama); Tani, J. (Takamatsu); Atsukawa, M. (Tokyo); Takaguchi, K. (Takamatsu); Itobayashi, E. (Asahi); Fukunishi, S. (Osaka); Tsuji, K. (Sapporo); Ishikawa, T. (Niigata); Tajiri, K. (Toyama); Ochi, H. (Matsuyama); Yasuda, S.; Toyoda, H. (Ogaki); Ogawa, C. (Takamatsu); Nishimura, T. (Nishinomiya); Hatanaka, T. (Maebashi); Kakizaki, S. (Takasaki); Shimada, N. (Kashiwa); Kawata, K. (Hamamatsu); Naganuma, A. (Takasaki); Kosaka, H. (Hirakata); Matono, T. (Himeji); Shibata, H. (Tokushima); Aoki, T. (Osaka); Tada, F. (Matsuyama); Nouse, K. (Okayama); Morishita, A.; Tsutsui, A.; Nagano, T. (Takamatsu); Itokawa, N.; Okubo, T.; Arai, T. (Tokyo); Imai, M. (Niigata); Koizumi, Y. (Toon); Nakamura, S. (Himeji); Iijima, H. (Nishinomiya); Kaibori, M. (Hirakata); Hiasa, Y. (Toon); Kudo, M. (Osaka); Kumada, T. (Ogaki)
- 553 Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm**
Hingorani, M. (Cottingham); Goody, R. (Leeds); Bozas, G.; Zahid, K.; Mitton, D.J.; Jain, P.; Wong, V.; Roy, R. (Cottingham)
- 565 Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study**
Ueno, M. (Wakayama); Kosaka, H. (Osaka); Iida, H. (Otsu); Ida, Y. (Wakayama); Aoi, K. (Osaka); Mori, H. (Otsu); Miyamoto, A. (Wakayama); Nishida, Y. (Osaka); Hayami, S.; Kawai, M. (Wakayama); Kaibori, M. (Osaka)
- 575 Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria**
Ohama, H.; Hiraoka, A.; Tada, F.; Kato, K.; Fukunishi, Y.; Yanagihara, E.; Kato, M.; Saneto, H.; Izumoto, H.; Ueki, H.; Yoshino, T.; Kitahata, S.; Kawamura, T.; Kuroda, T.; Suga, Y.; Miyata, H. (Matsuyama); Hirooka, M.; Abe, M.; Matsuura, B. (Toon); Ninomiya, T. (Matsuyama); Hiasa, Y. (Toon)
- 584 Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy**
Hayashi, T. (Fukuoka); Shimokawa, M. (Yamaguchi); Matsuo, K.; Uchiyama, M. (Fukuoka); Kawada, K. (Nankoku); Nakano, T.; Egawa, T. (Fukuoka)

Reducing the Worldwide Burden of Cancer

- 591 Overexpression of SOX2 Gene by Histone Modifications: SOX2 Enhances Human Prostate and Breast Cancer Progression by Prevention of Apoptosis and Enhancing Cell Proliferation**
Kar, S.; Niharika; Roy, A.; Patra, S.K. (Rourkela)

Cover illustration
© S. Karger AG, Basel

Karger

© 2023 S. Karger AG, Basel

Access to full text and tables of contents,
including tentative ones for forthcoming issues:
www.karger.com/ocl